Genomic Testing
Guidance for Oncology
genoCDS chronicles genomic testing indicated across all cancer disease states — organized by disease, subtype, and staging — with structured evidence tiers, reflex testing algorithms, and payer coverage across six major insurers.
- Disease states
- 60+
- in roadmap
- Evidence sources
- 4
- FDA, ASCO, ESMO, OncoKB
- Payer policies tracked
- 6
- CMS + 5 national payers
- Standards aligned
- 5
- SNOMED, LOINC, ICD-10, FHIR, CQL
Current Disease Coverage
Phase 1 covers four disease groups. Additional solid tumors and hematologic malignancies are added on a rolling basis.
Non-Small Cell Lung Cancer
The most genetically complex solid tumor — 14+ actionable biomarkers guide first- and later-line therapy selection.
Breast Cancer
HER2, ER/PR, BRCA1/2, PIK3CA, and germline testing guide multi-modal treatment decisions.
Colorectal Cancer
RAS/BRAF mutational status and MMR/MSI are essential for anti-EGFR therapy and immunotherapy eligibility.
Lymphoma
WHO classification, cytogenetics, and molecular markers direct therapy in Hodgkin and Non-Hodgkin lymphoma.
How genoCDS Works
Select Disease & Subtype
Browse by disease group (solid tumors or hematologic malignancies), then refine to the specific molecular or histologic subtype.
Filter by Stage & Context
Specify the clinical context — pre-staging workup, at diagnosis, post-staging, or monitoring — and the applicable AJCC or WHO stage.
Review Testing Recommendations
See prioritized test recommendations with evidence tiers (FDA, OncoKB, ASCO, ESMO), reflex algorithms, specimen requirements, and payer coverage.
API Access for Health Systems
Programmatic access to structured genomic testing guidance for EMR integration and clinical workflow tools. Free for qualified health systems; licensed for commercial use.
Medical Disclaimer
genoCDS is a clinical reference tool for qualified healthcare professionals only. Content is derived from published guidelines and regulatory sources and may contain errors or outdated information. It is not a substitute for professional medical judgment, institutional protocols, or individual patient assessment. Always verify recommendations against current primary sources before making clinical decisions. Full disclaimer →